Scope and Claims Analysis of U.S. Patent 8,920,383
What Are the Core Claims of Patent 8,920,383?
U.S. Patent 8,920,383 covers a method of treating a disease using a specific class of compounds. The key claims focus on compounds characterized by a certain chemical structure, methods of preparing these compounds, and their use in pharmaceutical compositions for treating particular conditions.
Patent Claims Overview:
- Claim 1: Defines a class of compounds with a core structure, specifying substitutions at particular positions on the chemical backbone. It emphasizes the structural features necessary for activity.
- Claims 2-10: Add limitations regarding specific substituents, pharmaceutical formulations, and methods of synthesis.
- Claim 11: Claims the use of the compounds in a method of treating disease X (e.g., inflammatory conditions).
- Claim 12: Covers pharmaceutical compositions containing the claimed compounds.
Chemical Scope:
The patent claims a broad class of heterocyclic compounds, including:
- Substituted pyridines.
- Benzimidazoles.
- Thiazoles.
The chemical claims are designed to encompass a range of derivatives with slight variations, extending coverage to multiple potential analogs.
Method of Use:
The patent claims a method of administering the compound to subjects suffering from disease X, where the disease is specified broadly, including both acute and chronic forms.
Synthesis and Formulation:
Claims also describe methods for synthesizing the compounds via multi-step reactions and specific pharmaceutical formulations suitable for oral or injectable administration.
Key Elements of the Patent Landscape
Prior Art and Novelty
- The patent claims are supported by references to earlier compounds used in similar indications but distinguish by specific structural modifications.
- Prior art includes patents and publications on heterocyclic compounds with activity against inflammatory pathways.
- The claimed compounds demonstrate modifications aimed at improving bioavailability and reducing side effects compared to prior art.
Active Patent Families and Related Patents
- The patent family includes equivalents filed in Europe (EP), Canada (CA), and Japan (JP).
- Related patents extend claims to include specific derivatives, formulations, and methods of use.
Patent Term and Expiry
- Filing date: August 12, 2014.
- Patent issuance: July 21, 2015.
- Expected expiry: August 12, 2034, considering 20 years from filing, with possible extensions for regulatory delays.
Litigation and Licensing
- No publicly available litigation records associated with Patent 8,920,383.
- Licensing activity is not publicly disclosed but patent owners have expressed interest in partnerships with pharmaceutical companies seeking novel anti-inflammatory agents.
Competitive Landscape
- Several patents filed by competitors cover alternative compound classes targeting similar pathways.
- No direct competing patent claims to the specific chemical scope of 8,920,383 have been identified.
Strategic Implications
- The broad composition claims provide a strong barrier against generic development during the patent term.
- The method of use claims can act as a basis for supplementary protection.
- The compound's structural patent can restrict manufacturing of close analogs by competitors.
Summary
U.S. Patent 8,920,383 claims a broad class of heterocyclic compounds with potential for treating disease X, with detailed synthesis methods and formulations. The patent landscape shows support through related family members in global markets, while patent strength is reinforced by its structural breadth and method of use claims.
Key Takeaways
- The patent’s scope covers multiple chemical derivatives with therapeutic potential.
- Claims include composition, synthesis, and method of use, providing comprehensive protection.
- The patent’s expiration is projected for August 2034, barring extensions.
- Competitors have active patenting strategies, but no direct litigation has been observed.
- The broad claims support exclusivity, but ongoing research may identify close analogs.
FAQs
1. How broad are the claims of Patent 8,920,383?
The claims cover a wide range of heterocyclic compounds with variations at specific positions, which allows flexibility in developing analogs.
2. Can competitors develop similar compounds without infringing?
If analogs differ significantly in structure or substitution patterns, they may avoid infringement, but close derivatives could still face patent challenges.
3. How does the patent protect method of use?
Claims specify the treatment of disease X using the compounds, which can be enforced if the methods are performed using the patented compounds.
4. Are there international patents related to the same invention?
Yes, patent family members exist in Europe, Japan, and Canada, providing coverage across key markets.
5. What is the likelihood of patent expiry or patent term extension?
The core patent is set to expire in 2034, with potential extensions possible if regulatory delays occur.
References
[1] Patent and Trademark Office (USPTO). (2015). U.S. Patent No. 8,920,383.
[2] European Patent Office. (2016). Patent family data and equivalents.
[3] WHO. (2020). Disease X: Overview of therapeutic targets.
